The reported remission rates vary between 30% and 50%, the relapse rates between 50% and 80%, and the long-term survival between 30% and 50%; there is a five times higher risk of death compared with other non-NUP98::NDS1-mutated AML [7, 22]. Here, NUP98 is linked to acute myeloid leukemia.